Odyssey Therapeutics Announces Presentation Of Additional Phase 2a OD-001 Ulcerative Colitis Data At UEG Week On October 20
Share
Why It Matters
Odyssey Therapeutics is showing more test results for a medicine treating ulcerative colitis. Watch if doctors and investors think the medicine is working well enough.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.